Coagulation Factor IX for Hemophilia B Therapy

  • Orlova N
  • Kovnir S
  • Vorobiev I
  • et al.
N/ACitations
Citations of this article
79Readers
Mendeley users who have this article in their library.

Abstract

Factor IX is a zymogen enzyme of the blood coagulation cascade. Inherited absence or deficit of the IX functional factor causes bleeding disorder hemophilia B, which requires constant protein replacement therapy. Reviewed herein are the current state in the manufacturing of FIX, improved variants of the recombinant protein for therapy, transgenic organisms for obtaining FIX, and the advances in the gene therapy of hemophilia B.

Cite

CITATION STYLE

APA

Orlova, N. A., Kovnir, S. V., Vorobiev, I. I., & Gabibov, A. G. (2012). Coagulation Factor IX for Hemophilia B Therapy. Acta Naturae, 4(2), 62–73. https://doi.org/10.32607/20758251-2012-4-2-62-73

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free